-
China’s Healthcare Bureaus Remove Drug Quantity Limits to Enhance NRDL Access
•
The healthcare security administration bureaus in Shanghai, Beijing, and other regions have recently removed limits on drug use quantities in hospitals. This move is aimed at bolstering the access of drugs listed on the National Reimbursement Drug List (NRDL) to healthcare facilities. Shanghai’s Initiatives for NRDL Drug ProcurementShanghai’s healthcare security…
-
Beijing Releases List of Novel Drugs and Technologies Exempt from CHS-DRG Payment Scheme
•
The Beijing Municipal Medical Insurance Bureau has released the list of the first batch of novel drugs and technologies that will enjoy payment outside of the China Health-care Security Diagnosis Related Groups (CHS-DRG) payment scheme. A total of 24 payment items are included, featuring small molecule inhibitors such as olaparib,…
-
NHSA to Announce NRDL Adjustment Results at November 28th Press Conference
•
The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price bidding for the National Reimbursement Drug List (NRDL) adjustment at a press conference scheduled for 10:00 am on November 28th. This event marks a significant moment in the healthcare sector as it will disclose the…
-
China’s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List
•
According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding the National Reimbursement Drug List (NRDL) price negotiation occurred from October 16 to 18. These pre-negotiation talks, which serve as one-on-one communications prior to the formal negotiation process, were divided into three groups this year.…
-
NHSA Updates NRDL Review, Adds Three Domestic Western Medicines
•
The National Healthcare Security Administration (NHSA) has issued a notification regarding the review and correction of results related to drugs on the preliminary formal review list of the National Reimbursement Drug List (NRDL). This update follows feedback collected from August 7 to 13, 2024. The revised list now includes 249…
-
Beijing Unveils Action Plan to Boost Pharmaceutical and Health Industry by 2026
•
The Beijing People’s Government has issued an “Action Plan” outlining measures and targets to “Accelerate Collaborative Innovation in Medicine and Health” over a three-year period from 2024 to 2026. Many of these measures were previously outlined in a draft document reported in April 2024. The plan sets an ambitious goal…
-
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
•
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth quarter and full-year 2023, with a 5% year-on-year (YOY) growth to GBP 30.3 billion (USD 38.5 billion) in revenue over the 12-month period. When excluding the impact of COVID-related products, the company’s sales surged by…
-
Hunan Province Hospitals Commit to Implementing Nationally Negotiated Drugs in Policy Seminar
•
A policy seminar under the auspices of the Hunan Healthcare Security Administration bureau convened in Changsha, the capital of Hunan province, with the objective of ensuring the implementation of newly nationally negotiated drugs included in the National Reimbursement Drug List (NRDL). The event resulted in a consensus among hospital leaders…
-
EU Chamber of Commerce in China Releases Position Paper, Addresses Pharma and Healthcare
•
The EU Chamber of Commerce in China has released its bi-annual “European Business in China Position Paper 2023/2024,” which compiles recommendations from over 1,700 member companies. The document aims to foster constructive dialogue between Europe and China, enhancing engagement between European firms and Chinese stakeholders for mutual benefit. The paper…
-
NHSA Releases Official Guidelines for Drug Negotiations and Bidding for NRDL Update
•
The National Healthcare Security Administration (NHSA) has officially released the “Negotiation Drug Renewals” and “Non-exclusive Drug Bidding” guidelines for the annual update to the National Reimbursement Drug List (NRDL). These guidelines outline the processes for drug negotiations and bidding, ensuring transparency and efficiency in the management of drugs included in…
-
NHSA Unveils 2023 Work Plan for National Reimbursement Drug List Update
•
The National Healthcare Security Administration (NHSA) has released the “Work Plan for the National Reimbursement Drug List (NRDL) Update, 2023”, following an earlier draft proposal for this year’s NRDL update. The document contains no significant surprises and aligns with the rules used for the 2022 update. Eligibility and Update Rules…
-
Anhui and Qinghai Provinces Update BMI Chronic Disease Drug Lists for Outpatient Reimbursement
•
The healthcare security bureaus of Anhui and Qinghai provinces in China have separately released notifications regarding the adjustment of the basic medical insurance (BMI) chronic disease drug lists for outpatients. These lists are significant as they often result in improved reimbursement conditions for patients and can lead to certain drugs…
-
China’s Premier Li Keqiang Highlights Economic and Social Advances in Annual Report
•
Premier Li Keqiang delivered his annual Government Work Report at the “Two Sessions” meeting, which includes the National People’s Congress and commenced this week in Beijing. The report highlighted significant economic and social advancements, reflecting the government’s efforts in various sectors. Economic HighlightsDuring 2022, China’s national GDP reached RMB 121…
-
China’s NRDL Update and Expansion of ‘Dual Channel’ Drug Access
•
The latest update to China’s National Reimbursement Drug List (NRDL) was implemented from March 1, 2023. Alongside this, Shanghai released a list of 383 drugs that will be involved in the “dual channel” management system. This initiative allows insured patients in Shanghai to purchase these drugs at designated retail pharmacies…
-
China’s NRDL Update: New Drugs Available for Online Procurement
•
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) drug procurement platform has released a notice stating that drugs newly added to the 2022 edition of the National Reimbursement Drug List (NRDL) are now available for online procurement by hospitals. The 2022 NRDL update, which was completed in mid-January 2023, includes 111 newly…
-
Beijing HSA Sets Price for Hainan Simcere’s COVID-19 Therapy SIM0417
•
Beijing’s municipal Healthcare Security Administration (HSA) bureau has released details of the initial quote and Chinese market price for Hainan Simcere Pharmaceutical Co., Ltd’s recently approved small-molecule COVID-19 therapy, SIM0417. The drug will be launched at RMB 750 (USD 111) per box, with an ex-factory price including tax (or CIF…
-
Fosun Foundation Donates COVID-19 Therapy Azvudine to Rural China
•
The Fosun Foundation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Henan Genuine Biotech Co., Ltd have announced the donation of RMB 100 million (USD 14.76 million) worth of the oral COVID-19 therapy azvudine to 180 counties in middle and western rural China. The donation will be…
-
China Optimizes Medical Insurance Policies for COVID-19 Treatment
•
The National Healthcare Security Administration (NHSA), Ministry of Finance, National Health Commission, and Chinese Center for Disease Control and Prevention have released a Notice on “Optimizing Relevant Medical Insurance Policies for Treatment Expenses of Patients with Novel Coronavirus Infection after Implementation of ‘Class B and Class B Management’”. The guidelines…
-
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Faces FDA Review Delay
•
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that they have not received an action letter from the US FDA regarding the Biologics License Application (BLA) for the programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab). The ongoing delay is attributed to the failure to inspect the manufacturing site. The…
-
NHSA Delays NRDL Negotiations Due to COVID-19 Disruptions
•
The National Healthcare Security Administration (NHSA) announced that it has been decided to delay the National Reimbursement Drug List (NRDL) on-site negotiations process for this year, citing COVID-19 disruptions and ongoing workload related to preparing for the negotiations. When a new time slot is decided, the negotiating groups will be…
